Mirabegron (Myrbetriq) for Urge Urinary Incontinence
Start mirabegron 25 mg once daily for urge urinary incontinence only after bladder training has failed, and titrate to 50 mg after 4-8 weeks if symptoms persist. 1, 2
Clinical Context and Positioning
Mirabegron is a beta-3 adrenergic agonist that should be positioned as second-line pharmacotherapy for urgency urinary incontinence, not first-line treatment. The ACP guidelines strongly recommend bladder training as initial therapy for urgency UI, with pharmacologic treatment reserved for patients who fail behavioral interventions 1. This stepwise approach prioritizes therapies with fewer adverse effects and lower costs while maintaining effectiveness.
Initiation Protocol
Starting Dose
- Adults: Begin with 25 mg orally once daily 2
- Can be taken with or without food in adults 2
- Swallow tablets whole—do not chew, divide, or crush 2
Patient Selection Considerations
Preferred candidates for mirabegron over antimuscarinics 3:
- Patients at risk for cognitive dysfunction
- History of severe dry mouth with antimuscarinics
- History of constipation
- Prior urinary retention episodes
- Elderly patients with low detrusor contractility
- Men with benign prostatic hyperplasia
Titration Strategy
After 4-8 weeks at 25 mg, increase to 50 mg once daily if:
- Residual daily urgency episodes persist
- Urgency urinary incontinence episodes continue
- Patient tolerates initial dose without adverse effects 2, 4
The evidence shows that dose escalation from 25 mg to 50 mg significantly improves outcomes in patients with residual symptoms—60.9% reduction in daily urgency episodes versus 34.5% with continued 25 mg, and 87.5% reduction in UUI episodes versus 37.5% 4.
Contraindications
Absolute contraindication 2:
- Hypersensitivity to mirabegron or any inactive ingredients
Relative contraindication:
- Severe uncontrolled hypertension (medication not recommended) 2
Monitoring Requirements
Blood Pressure Surveillance
Monitor blood pressure periodically, especially in hypertensive patients 2. While mean changes are minimal (0.2-0.4 mmHg increase in systolic BP at 50-100 mg doses) 5, hypertension is the most common adverse event reported in clinical trials 2.
Specific Monitoring Points:
- Baseline: Blood pressure measurement before initiation
- Follow-up: BP checks at 4-8 weeks (titration visit) and periodically thereafter
- High-risk patients: More frequent monitoring in those with pre-existing hypertension
Urinary Retention Risk
Use with caution in patients with bladder outlet obstruction or those taking antimuscarinic medications concurrently, as urinary retention risk increases 2. However, mirabegron does not significantly affect post-void residual volumes in most patients 6.
Dose Adjustments for Special Populations
Renal Impairment
- Severe renal impairment (CrCl 15-29 mL/min): Maximum dose 25 mg daily
- End-stage renal disease (CrCl <15 mL/min): Not recommended 2
Hepatic Impairment
- Moderate hepatic impairment (Child-Pugh Class B): Maximum dose 25 mg daily
- Severe hepatic impairment (Child-Pugh Class C): Not recommended 2
Expected Adverse Effects
The most common adverse events (>2% and greater than placebo) 2:
- Hypertension
- Nasopharyngitis
- Urinary tract infection
- Headache
Notably absent: Dry mouth occurs at rates similar to placebo (2.8% for mirabegron 50 mg versus 8.6% for tolterodine) 5, 7, making this a significant advantage over antimuscarinics where dry mouth is the primary reason for discontinuation 1.
Rare but serious: Angioedema of face, lips, tongue, and/or larynx has been reported 2.
Treatment Response Timeline
Expect improvements as early as 4 weeks after initiation, with sustained efficacy throughout long-term treatment 5, 7. In 12-month studies, mirabegron demonstrated maintained efficacy with improvements in:
- Micturition frequency
- Urgency incontinence episodes
- Mean volume voided per micturition
Combination Therapy Approach
If monotherapy with mirabegron 50 mg fails to achieve adequate symptom control:
- First: Try switching to an antimuscarinic agent
- Second: If switching fails, consider combination therapy with mirabegron plus an antimuscarinic 3
The 2024 AUA/SUFU guidelines support combining therapies when monotherapy is insufficient 8, though this should be done systematically rather than adding multiple agents simultaneously.
Common Pitfalls to Avoid
- Starting with pharmacotherapy before behavioral interventions: This violates guideline recommendations and exposes patients to unnecessary medication risks 1
- Inadequate trial duration: Assess response at 4-8 weeks before declaring treatment failure
- Failing to titrate: Many patients benefit from dose escalation to 50 mg who had partial response to 25 mg 4
- Ignoring blood pressure monitoring: Hypertension is the most common adverse event and requires surveillance 2
- Using in severe uncontrolled hypertension: This is explicitly not recommended 2